Our rapid review process allows you to determine the pricing and access potential of your in/out licensing asset.
Expert Support
Realise the value of an asset
We help you to understand the value of an asset during the in-licensing and out-licensing process
We can evaluate the potential commercial value of an asset through identification of the patient flow and determining the price and reimbursement potential, providing insights on how to improve the asset’s value through the identification of clinical and economic evidence that will resonate with stakeholders
Our ‘Pricing and Market Access Rapid Review’ process is tailored to provide the top-line insights required to feed into your due diligence process
Dissecting the First EU JCA
The first EU Joint Clinical Assessment (JCA) has now been published, but with so many perspectives already in the market, the real question is: what does it actually mean for your next submission?
Rather than revisiting the theory, this webinar focuses on key strategic signals revealed by the first JCA. Using the assessment of tovorafenib as a case study, we will examine what happened in practice and explore the implications for manufacturers preparing upcoming submissions.
Hosted by Paul Craddy, Charlie Hewitt & Lauren Boland